Table 3.
Clinical implications of VPA in glioma patients.
| Patients | Concentration (VPA) | Other Therapeutic Agents | Clinical Implications | Ref. |
|---|---|---|---|---|
| 38 children with DIPGs or HGGs | 15 mg/kg/day | Radiation: 50.4–54 Gy | ↑EFS, ↑OS | (37) |
| 112 patients with HGGs | 800 mg/day | TMZ: 75 mg/m2/day Radiation: 60 Gy |
↓hair loss, ↑OS, ↑PFS | (38) |
| 165 GBM patients | 10–15 mg/kg/day | Radiation: 18 Gy Carboplatin: 175 mg/m2 Vincristine: 1.5 mg/m2 |
↑median event-free survival, ↑median survival | (39) |
| 44 glioma patients | 10 mg/kg/day in week 1 20 mg/kg/day in week 2 |
\ | ↑median overall survival, ↓toxicity | (40) |
| 2379 HGG patients | ≥84 DDD (1,212) <84 DDD (1,167) |
TMZ: 75 mg/m2/day | ↑OS, ↓hazard ratio | (41) |
| 359 glioma patients (WHO II-IV) | GBM patients (0.49–1825 g) Grade II/III patients (10.5–4,106.25 g). |
TMZ: 75 mg/m2/day | ↑OS (GBM) ↓histological progression, ↑PFS (Grade II/III) |
(42) |
VPA, valproic acid; DIPG, diffuse intrinsic pontine glioma; HGG, high-grade glioma; EFS, event-free survival; OS, overall survival; TMZ, temozolomide; PFS, progression-free survival; DDD, defined daily dose.
↓ -Inhibition, ↑ -Promotion.